Rusfertide is a synthetic hepcidin mimetic peptide designed to mimic the activity of natural hepcidin, the master iron-regulator hormone. By limiting the iron available for erythropoiesis, rusfertide constrains red blood cell production in patients whose disease drives pathological overproduction.
The FDA approved rusfertide as Mimrylo on Friday August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions, anemia, and fatigue. Rusfertide had received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA. Jefferies analysts project peak sales potential of $2 billion.
Rusfertide was originally developed by Protagonist Therapeutics (NASDAQ: PTGX) using its platform of orally-stable and injection-stable peptide therapeutics. In January 2024, Protagonist and Takeda (NYSE: TAK) entered into a worldwide license and collaboration agreement; Takeda is commercializing Mimrylo globally, and the approval triggered $275 million in milestone payments to Protagonist ($200 million opt-out fee plus $75 million approval milestone). Stories here cover clinical readouts, launch trajectory, follow-on indications, and the broader hepcidin mimetic category. See #protagonist-therapeutics, #takeda, and #polycythemia-vera for adjacent threads.
Takeda (NYSE: TAK) confirmed Sunday August 30, 2026 that commercial launch of Mimrylo (rusfertide, the first-in-class subcutaneous hepcidin mimetic peptide approved Friday August 28 for erythrocytosis in adults with polycythemia vera) is underway across the U.S., with the product available at specialty pharmacies within 48 hours of FDA approval. The commercial launch approach reflects Takeda's rare-blood-cancer specialty commercial infrastructure built up around Iclusig (ponatinib) for chronic myeloid leukemia and the recent Fruzaqla (fruquintinib) launch in colorectal cancer. Jefferies analyst projections of $2 billion peak sales assume rapid coverage decisions from major U.S. payers by end of 2026 plus European approval on the same clinical dataset in H1 2027. The Mimrylo launch establishes the hepcidin mimetic peptide category and sets a commercial template that Disc Medicine's DISC-0974 (an anti-hemojuvelin antibody targeting hepcidin from a different angle) and Silence Therapeutics' SLN124 (siRNA targeting TMPRSS6, an upstream hepcidin regulator) will need to differentiate against.
Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.
Protagonist Therapeutics (Nasdaq: PTGX) and Takeda are presenting four rusfertide abstracts at the 2026 European Hematology Association Congress in Stockholm (June 11-14), including analyses from the Phase 3 VERIFY study and long-term results from the Phase 2 REVIVE and THRIVE open-label extensions. The 32-week VERIFY primary analysis showed 76.9% of patients on rusfertide achieved a clinical response versus 32.9% on placebo; the 52-week dataset met the primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class subcutaneous hepcidin-mimetic peptide for polycythemia vera. The FDA accepted the rusfertide NDA in early 2026 with priority review and set a Q3 2026 PDUFA target action date.
Takeda/Protagonist Therapeutics' rusfertide, a first-in-class hepcidin mimetic peptide, received NDA acceptance and priority review. The Phase 3 VERIFY study showed it more than doubled clinical response rates.